ArticleCPT: pharmacometrics & systems pharmacology2022

Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.

Fatiha Rachedi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.